NCT06487572View on ClinicalTrials.gov

A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 23, 2024

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab

Intravenous (IV) Infusion

DRUG

Risankizumab

Subcutaneous (SC) Injection

Trial Locations (2)

33014

Clinical Pharmacology Of Miami /ID# 268219, Miami

60030

Acpru /Id# 267057, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY